These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15330682)

  • 21. Gliclazide modified release.
    McGavin JK; Perry CM; Goa KL
    Drugs; 2002; 62(9):1357-64; discussion 1365-6. PubMed ID: 12076188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials.
    Metzmann K; Schnell D; Jungnik A; Ring A; Theodor R; Hohl K; Meinicke T; Friedrich C
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):549-63. PubMed ID: 24755124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
    Murphy J; Wang SS; Stieltjes H; Wajs E; Devineni D
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):256-64. PubMed ID: 25546166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
    DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
    J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-composition extended-release metformin hydrochloride. A viewpoint by Vivian Fonseca.
    Fonseca V
    Treat Endocrinol; 2004; 3(5):333-4. PubMed ID: 15330684
    [No Abstract]   [Full Text] [Related]  

  • 27. Single-composition extended-release metformin hydrochloride. A viewpoint by David Bell.
    Bell D
    Treat Endocrinol; 2004; 3(5):333. PubMed ID: 15330683
    [No Abstract]   [Full Text] [Related]  

  • 28. [The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].
    Kołodziejczyk MK; Kołodziejska J; Zgoda MM
    Polim Med; 2012; 42(3-4):167-84. PubMed ID: 23457958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.
    Duong JK; Kumar SS; Kirkpatrick CM; Greenup LC; Arora M; Lee TC; Timmins P; Graham GG; Furlong TJ; Greenfield JR; Williams KM; Day RO
    Clin Pharmacokinet; 2013 May; 52(5):373-84. PubMed ID: 23475568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
    Buse JB; DeFronzo RA; Rosenstock J; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetes Care; 2016 Feb; 39(2):198-205. PubMed ID: 26285584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study.
    Donnelly LA; Morris AD; Pearson ER
    Diabetes Obes Metab; 2009 Apr; 11(4):338-42. PubMed ID: 19267712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin.
    Oh JH; Eun Lee J; Jeong Kim Y; Oh TO; Han S; Jeon EK; Shin K; Kim DH; Hye Park C; Lee YJ
    Drug Dev Ind Pharm; 2016; 42(2):340-9. PubMed ID: 26467296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
    Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
    Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
    Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
    Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative Pharmacokinetics of a Controlled-release Pregabalin Tablet (GLA5PR GLARS-NF1) and an Immediate-release Pregabalin Capsule in Healthy Male Volunteers.
    Kim TE; Jeon JY; Gu N; Chang Kwon M; Kim MG
    Clin Ther; 2018 Dec; 40(12):2112-2124. PubMed ID: 30497798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of extended-release metformin core tablet and synergistic coating of sitagliptin for the treatment of type-II diabetes mellitus - A comparative drug release evaluation with reference product.
    Ahmed A; Wasim AA; Fazal-Ur-Rehman S; Ali M
    Pak J Pharm Sci; 2022 Sep; 35(5):1473-1480. PubMed ID: 36451578
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active coating of immediate-release evogliptin tartrate to prepare fixed dose combination tablet with sustained-release metformin HCl.
    Han Won D; Park H; Seo JW; Woo Jang S; Ha ES; Kim MS
    Int J Pharm; 2022 Jul; 623():121927. PubMed ID: 35716979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Visualized analysis and evaluation of simultaneous controlled release of metformin hydrochloride and gliclazide from sandwiched osmotic pump capsule.
    Gao S; Chen Y; Hu R; Lu W; Yu L; Chen J; Liu S; Guo Y; Shen Q; Wang B; Fang W
    Drug Dev Ind Pharm; 2020 Nov; 46(11):1776-1786. PubMed ID: 32895014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.